Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | GBA1 | P04062 | 2/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4764220 | 0.83 | MAPT (0.41) | MAOB | |
| SCHEMBL27532142 | 0.83 | MAPT (0.37) | MAOB | |
| SCHEMBL27748779 | 0.81 | GBA1 (0.44) | GBA1SLC6A2SLC6A4SLC6A3POLB | |
| SCHEMBL17397341 | 0.81 | TAAR1 (0.37) | MAOB | |
| SCHEMBL28593515 | 0.81 | MEN1 (0.40) | MAOBSLC6A2SLC6A3 | |
| SCHEMBL7297026 | 0.78 | MAOB (0.42) | MAOB | |
| SCHEMBL8120694 | 0.77 | GBA1 (0.49) | GBA1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL28600129 | 0.77 | LMNA (0.40) | MAOBSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL9120225 | 0.77 | MAOB (0.50) | MAOBGBA1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6916462 | 0.72 | GBA1 (0.43) | GBA1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1757582-B1 | ARYLALKYLAMINES AND PROCESS FOR PRODUCTION THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2015-12-30 | — | — | EP | claimed |
| US-8778628-B2 | Arylalkylamine compound and process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-07-15 | — | — | US | claimed |
| US-20140080770-A1 | ARYLALKYLAMINE COMPOUND AND PROCESS FOR PREPARING THE SAME | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-03-20 | — | — | US | claimed |
| US-20100249049-A1 | ARYLALKYLAMINE COMPOUND AND PROCESS FOR PREPARING THE SAME | MIYAZAKI HIROSHI | 2010-09-30 | — | — | US | claimed |
| US-20070225296-A1 | Arylalkylamine Compound and Process for Preparing the Same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-09-27 | — | — | US | claimed |
| EP-1757582-A1 | ARYLALKYLAMINES AND PROCESS FOR PRODUCTION THEREOF | TANABE SEIYAKU CO., LTD. (JP) | 2007-02-28 | — | — | EP | claimed |
| EP-1757582-B1 | ARYLALKYLAMINES AND PROCESS FOR PRODUCTION THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2015-12-30 | — | — | EP | disclosed |
| US-8778628-B2 | Arylalkylamine compound and process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-07-15 | — | — | US | disclosed |
| US-8759387-B2 | Arylalkylamine compound and process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-06-24 | — | — | US | disclosed |
| US-8703721-B2 | Arylalkylamine compound and process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-04-22 | — | — | US | disclosed |
| US-20140080770-A1 | ARYLALKYLAMINE COMPOUND AND PROCESS FOR PREPARING THE SAME | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-03-20 | — | — | US | disclosed |
| US-8492111-B2 | Arylalkylamine compound and process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-07-23 | — | — | US | disclosed |
| US-20130150374-A1 | ARYLALKYLAMINE COMPOUND AND PROCESS FOR PREPARING THE SAME | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-06-13 | — | — | US | disclosed |
| US-20110218160-A1 | ARYLALKYLAMINE COMPOUND AND PROCESS FOR PREPARING THE SAME | MIYAZAKI HIROSHI | 2011-09-08 | — | — | US | disclosed |
| WO-2010121873-A1 | COMPOSITION CONTAINING QUATERNARY AMINO-FUNCTIONAL ORGANOSILICON COMPOUNDS AND PRODUCTION AND USE THEREOF | EVONIK DEGUSSA GMBH (DE) | 2010-10-28 | — | — | WO | disclosed |
| US-20100249049-A1 | ARYLALKYLAMINE COMPOUND AND PROCESS FOR PREPARING THE SAME | MIYAZAKI HIROSHI | 2010-09-30 | — | — | US | disclosed |
| US-20070225296-A1 | Arylalkylamine Compound and Process for Preparing the Same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-09-27 | — | — | US | disclosed |
| EP-1757582-A1 | ARYLALKYLAMINES AND PROCESS FOR PRODUCTION THEREOF | TANABE SEIYAKU CO., LTD. (JP) | 2007-02-28 | — | — | EP | disclosed |
| CN-1040792-A | ANTIFUNGAL AGENTS BASED ON AMIDES CONTAINING PHENYL GROUP | RHONE POULENC AGROCHIMIE (FR) | 1990-03-28 | — | — | CN | disclosed |
| US-4016263-A | BACTERICIDES | BOEHRINGER INGELHEIM GMBH (DT) | 1977-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080770-A1 | ARYLALKYLAMINE COMPOUND AND PROCESS FOR PREPARING THE SAME | NAT1, INMT, ARSA | MAOB 108/4885GBA1 56/4885SLC6A2 60/4885 |
| US-20110218160-A1 | ARYLALKYLAMINE COMPOUND AND PROCESS FOR PREPARING THE SAME | CASR, CNR1, CNR2 | MAOB 1788/4885GBA1 3022/4885SLC6A2 1337/4885 |
| US-20130150374-A1 | ARYLALKYLAMINE COMPOUND AND PROCESS FOR PREPARING THE SAME | CASR, CNR1, HCAR1 | MAOB 1771/4885GBA1 3035/4885SLC6A2 1367/4885 |
| US-20070225296-A1 | Arylalkylamine Compound and Process for Preparing the Same | CASR, CNR1, CNR2 | MAOB 1788/4885GBA1 3022/4885SLC6A2 1337/4885 |
| US-20100249049-A1 | ARYLALKYLAMINE COMPOUND AND PROCESS FOR PREPARING THE SAME | CASR, CNR1, CNR2 | MAOB 1788/4885GBA1 3022/4885SLC6A2 1337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.